Sumitomo Pharma Co Ltd 2021 Integrated Report
The report presents Sumitomo Pharma Co., Ltd.'s Integrated Report 2022 for the fiscal year ended March 31, 2022. It highlights the company's rebranding from Sumitomo Dainippon Pharma to Sumitomo Pharma and its strategic focus on Psychiatry & Neurology, Oncology, Regenerative Medicine/Cell Therapy, and Frontier Business. The report details efforts to rebuild its business foundation, advance digital transformation, and pursue long-term environmental targets, including achieving zero greenhouse gas emissions by 2050.
Company: Sumitomo Pharma Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2021
Type: Integrated Report
Pages: 122
Back to company
Sumitomo Pharma Co Ltd
Integrated Report
The report presents Sumitomo Pharma Co., Ltd.'s Integrated Report 2022 for the fiscal year ended March 31, 2022. It highlights the company's rebranding from Sumitomo Dainippon Pharma to Sumitomo Pharma and its strategic focus on Psychiatry & Neurology, Oncology, Regenerative Medicine/Cell Therapy, and Frontier Business. The report details efforts to rebuild its business foundation, advance digital transformation, and pursue long-term environmental targets, including achieving zero greenhouse gas emissions by 2050.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2021
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees